Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients.
COVID-19
Children SARS-CoV-2 infection
Neutralizing antibodies
Peptide biomarkers
Peptide microarray
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
14 02 2023
14 02 2023
Historique:
received:
03
01
2023
accepted:
02
02
2023
entrez:
15
2
2023
pubmed:
16
2
2023
medline:
17
2
2023
Statut:
epublish
Résumé
The infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has unpredictable manifestations of coronavirus disease (COVID-19) and variable clinical course with some patients being asymptomatic whereas others experiencing severe respiratory distress, or even death. We aimed to evaluate the immunoglobulin G (IgG) response towards linear peptides on a peptide array containing sequences from SARS-CoV-2, Middle East respiratory syndrome-related coronavirus (MERS) and common-cold coronaviruses 229E, OC43, NL63 and HKU1 antigens, in order to identify immunological indicators of disease outcome in SARS-CoV-2 infected patients. We included in the study 79 subjects, comprising 19 pediatric and 30 adult SARS-CoV-2 infected patients with increasing disease severity, from mild to critical illness, and 30 uninfected subjects who were vaccinated with one dose of SARS-CoV-2 spike mRNA BNT162b2 vaccine. Serum samples were analyzed by a peptide microarray containing 5828 overlapping 15-mer synthetic peptides corresponding to the full SARS-CoV-2 proteome and selected linear epitopes of spike (S), envelope (E) and membrane (M) glycoproteins as well as nucleoprotein (N) of MERS, SARS and coronaviruses 229E, OC43, NL63 and HKU1 (isolates 1, 2 and 5). All patients exhibited high IgG reactivity against the central region and C-terminus peptides of both SARS-CoV-2 N and S proteins. Setting the threshold value for serum reactivity above 25,000 units, 100% and 81% of patients with severe disease, 36% and 29% of subjects with mild symptoms, and 8% and 17% of children younger than 8-years reacted against N and S proteins, respectively. Overall, the total number of peptides in the SARS-CoV-2 proteome targeted by serum samples was much higher in children compared to adults. Notably, we revealed a differential antibody response to SARS-CoV-2 peptides of M protein between adults, mainly reacting against the C-terminus epitopes, and children, who were highly responsive to the N-terminus of M protein. In addition, IgG signals against NS7B, NS8 and ORF10 peptides were found elevated mainly among adults with mild (63%) symptoms. Antibodies towards S and N proteins of other coronaviruses (MERS, 229E, OC43, NL63 and HKU1) were detected in all groups without a significant correlation with SARS-CoV-2 antibody levels. Overall, our results showed that antibodies elicited by specific linear epitopes of SARS-CoV-2 proteome are age dependent and related to COVID-19 clinical severity. Cross-reaction of antibodies to epitopes of other human coronaviruses was evident in all patients with distinct profiles between children and adult patients. Several SARS-CoV-2 peptides identified in this study are of particular interest for the development of vaccines and diagnostic tests to predict the clinical outcome of SARS-CoV-2 infection.
Sections du résumé
BACKGROUND
The infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has unpredictable manifestations of coronavirus disease (COVID-19) and variable clinical course with some patients being asymptomatic whereas others experiencing severe respiratory distress, or even death. We aimed to evaluate the immunoglobulin G (IgG) response towards linear peptides on a peptide array containing sequences from SARS-CoV-2, Middle East respiratory syndrome-related coronavirus (MERS) and common-cold coronaviruses 229E, OC43, NL63 and HKU1 antigens, in order to identify immunological indicators of disease outcome in SARS-CoV-2 infected patients.
METHODS
We included in the study 79 subjects, comprising 19 pediatric and 30 adult SARS-CoV-2 infected patients with increasing disease severity, from mild to critical illness, and 30 uninfected subjects who were vaccinated with one dose of SARS-CoV-2 spike mRNA BNT162b2 vaccine. Serum samples were analyzed by a peptide microarray containing 5828 overlapping 15-mer synthetic peptides corresponding to the full SARS-CoV-2 proteome and selected linear epitopes of spike (S), envelope (E) and membrane (M) glycoproteins as well as nucleoprotein (N) of MERS, SARS and coronaviruses 229E, OC43, NL63 and HKU1 (isolates 1, 2 and 5).
RESULTS
All patients exhibited high IgG reactivity against the central region and C-terminus peptides of both SARS-CoV-2 N and S proteins. Setting the threshold value for serum reactivity above 25,000 units, 100% and 81% of patients with severe disease, 36% and 29% of subjects with mild symptoms, and 8% and 17% of children younger than 8-years reacted against N and S proteins, respectively. Overall, the total number of peptides in the SARS-CoV-2 proteome targeted by serum samples was much higher in children compared to adults. Notably, we revealed a differential antibody response to SARS-CoV-2 peptides of M protein between adults, mainly reacting against the C-terminus epitopes, and children, who were highly responsive to the N-terminus of M protein. In addition, IgG signals against NS7B, NS8 and ORF10 peptides were found elevated mainly among adults with mild (63%) symptoms. Antibodies towards S and N proteins of other coronaviruses (MERS, 229E, OC43, NL63 and HKU1) were detected in all groups without a significant correlation with SARS-CoV-2 antibody levels.
CONCLUSIONS
Overall, our results showed that antibodies elicited by specific linear epitopes of SARS-CoV-2 proteome are age dependent and related to COVID-19 clinical severity. Cross-reaction of antibodies to epitopes of other human coronaviruses was evident in all patients with distinct profiles between children and adult patients. Several SARS-CoV-2 peptides identified in this study are of particular interest for the development of vaccines and diagnostic tests to predict the clinical outcome of SARS-CoV-2 infection.
Identifiants
pubmed: 36788606
doi: 10.1186/s12967-023-03963-5
pii: 10.1186/s12967-023-03963-5
pmc: PMC9927035
doi:
Substances chimiques
Antibodies, Viral
0
BNT162 Vaccine
0
Epitopes
0
Immunoglobulin G
0
Proteome
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
123Informations de copyright
© 2023. The Author(s).
Références
Nat Rev Microbiol. 2021 Nov;19(11):685-700
pubmed: 34535791
Virus Res. 2014 Dec 19;194:175-83
pubmed: 24670324
Ann Acad Med Singap. 2020 Aug;49(8):530-537
pubmed: 33164022
J Immunol Methods. 2015 Jan;416:105-23
pubmed: 25445329
Cureus. 2020 Mar 26;12(3):e7423
pubmed: 32337143
Front Immunol. 2020 Oct 16;11:586984
pubmed: 33178220
Front Immunol. 2021 Jul 07;12:708264
pubmed: 34305949
EBioMedicine. 2020 Aug;58:102911
pubmed: 32711254
Acta Pharmacol Sin. 2022 Dec;43(12):3021-3033
pubmed: 35058587
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
Front Endocrinol (Lausanne). 2020 Oct 05;11:574541
pubmed: 33123093
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Sci Rep. 2020 Oct 9;10(1):16944
pubmed: 33037310
Bioengineering (Basel). 2022 Feb 12;9(2):
pubmed: 35200425
EMBO J. 2021 Mar 1;40(5):e106228
pubmed: 33258165
J Infect. 2021 Oct;83(4):e9-e10
pubmed: 34384812
Int J Soc Psychiatry. 2020 Dec;66(8):748-755
pubmed: 32650687
Sci Immunol. 2020 Jun 11;5(48):
pubmed: 32527802
Microbiol Spectr. 2021 Oct 31;9(2):e0141621
pubmed: 34704808
Cochrane Database Syst Rev. 2022 Jun 17;6:CD014945
pubmed: 35713300
Commun Biol. 2021 Feb 12;4(1):225
pubmed: 33580175
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
J Immunol Methods. 2022 Jan;500:113197
pubmed: 34843712
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Nat Immunol. 2021 Nov;22(11):1452-1464
pubmed: 34611361
Nat Immunol. 2021 Jan;22(1):25-31
pubmed: 33154590
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Infect Dis. 2020 Jun 16;222(1):9-16
pubmed: 32246136
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Nat Biotechnol. 2022 Mar;40(3):319-324
pubmed: 34408314
Cell Rep. 2020 Jun 2;31(9):107725
pubmed: 32426212
J Immunol Methods. 2002 Sep 1;267(1):13-26
pubmed: 12135797
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Cell Mol Immunol. 2020 Oct;17(10):1095-1097
pubmed: 32895485
Front Immunol. 2021 Sep 30;12:741796
pubmed: 34659235
Cell Mol Immunol. 2020 May;17(5):539-540
pubmed: 32094505
Infect Drug Resist. 2021 Jun 16;14:2259-2268
pubmed: 34163190
Infect Agent Cancer. 2022 Jul 28;17(1):40
pubmed: 35902961
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Eur J Immunol. 2021 Jul;51(7):1839-1849
pubmed: 33772767
Pediatr Res. 2022 Jun 23;:
pubmed: 35739259
Cell Rep. 2021 Mar 30;34(13):108915
pubmed: 33761319
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):407-412
pubmed: 32335367
BMC Infect Dis. 2021 Jan 20;21(1):87
pubmed: 33472588
Nat Immunol. 2022 Feb;23(2):177-185
pubmed: 35105983
J Med Virol. 2022 May;94(5):1967-1975
pubmed: 34967028
Cell Rep Med. 2021 Jan 19;2(1):100189
pubmed: 33495758
Virulence. 2022 Dec;13(1):890-902
pubmed: 35587156
Cell Rep. 2021 Oct 12;37(2):109822
pubmed: 34610292
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
Nat Commun. 2022 May 26;13(1):2951
pubmed: 35618731
Annu Rev Microbiol. 2019 Sep 8;73:529-557
pubmed: 31226023
Rev Med Virol. 2020 Sep;30(5):e2134
pubmed: 32618072
Front Med (Lausanne). 2020 Dec 03;7:594495
pubmed: 33344479
Immunity. 2021 Feb 9;54(2):340-354.e6
pubmed: 33567252
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Commun Biol. 2020 Dec 11;3(1):780
pubmed: 33311543
JCI Insight. 2021 Jul 8;6(13):
pubmed: 34081630
Euro Surveill. 2021 Apr;26(13):
pubmed: 33797390
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
mBio. 2021 Jan 19;12(1):
pubmed: 33468695